Evidence map›Paper›PMID 28676012›Full record

ReviewCurrent neuropharmacology2019

Statins and the Brain: More than Lipid Lowering Agents?

Anna Fracassi, Martina Marangoni, Pamela Rosso, Valentina Pallottini, Marco Fioramonti, Silvia Siteni, Marco Segatto

Abstract readReview
In one paragraph

Review in Current neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Effects of simvastatin on white matter integrity in healthy middle-aged adults.Annals of clinical and translational neurology · 2021
    Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Anna FracassiDepartment of Science, University of Rome "Roma Tre", Italy.
Martina MarangoniMedical Genetics Unit, University Hospital of Rome "Tor Vergata", Italy.
Pamela RossoDepartment of Science, University of Rome "Roma Tre", Italy.
Valentina PallottiniDepartment of Science, University of Rome "Roma Tre", Italy.
Marco FioramontiUniversite Libre de Bruxelles (ULB), IRIBHM, Bruxelles, Belgium.
Silvia SiteniDepartment of Science, University of Rome "Roma Tre", Italy.
Marco SegattoInstitute of Cell Biology and Neurobiology, National Research Council (CNR), Rome, Italy.
Sapienza University of Rome · ITUniversità Campus Bio-Medico · ITUniversité Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStatins represent a class of medications widely prescribed to efficiently treat dyslipidemia. These drugs inhibit 3-βhydroxy 3β-methylglutaryl Coenzyme A reductase (HMGR), the rate-limiting enzyme of mevalonate (MVA) pathway. Besides cholesterol, MVA pathway leads to the production of several other compounds, which are essential in the regulation of a plethora of biological activities, including in the central nervous system. For these reasons, statins are able to induce pleiotropic actions, and acquire increased interest as potential and novel modulators in brain processes, especially during pathological conditions.

objectiveThe purpose of this review is to summarize and examine the current knowledge about pharmacokinetic and pharmacodynamic properties of statins in the brain. In addition, effects of statin on brain diseases are discussed providing the most up-to-date information.

methodsRelevant scientific information was identified from PubMed database using the following keywords: statins and brain, central nervous system, neurological diseases, neurodegeneration, brain tumors, mood, stroke.

results315 scientific articles were selected and analyzed for the writing of this review article. Several papers highlighted that statin treatment is effective in preventing or ameliorating the symptomatology of a number of brain pathologies. However, other studies failed to demonstrate a neuroprotective effect.

conclusionEven though considerable research studies suggest pivotal functional outcomes induced by statin therapy, additional investigation is required to better determine the pharmacological effectiveness of statins in the brain, and support their clinical use in the management of different neuropathologies.

Indexed as

AnimalsBrainBrain DiseasesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRandomized Controlled Trials as TopicHydroxymethylglutaryl-CoA Reductase Inhibitorsbrainbrain tumorsmoodneurodegenerationneurological disorders.Statins

Identifiers

PMID28676012
PMCPMC6341496
OpenAlexW2726472716

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.